Market Cap$93.01B

Compare GSK Plc

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
GSK Plc - ADRGSK Plc - ADR14.84.03%37%2.51.3
marketMarket Avg53.21.27%29%-1.3
HealthcareHealthcare Avg29.71.32%16%7.31.3

Earnings Call Q4 2023

January 31, 2024 - AI Summary

GSK reported strong performance in 2023, with sales growth of 14% and adjusted operating profit growth of 16%.
The company expects another year of meaningful growth in 2024, with sales growth projected to be between 5% and 7%, adjusted operating profit growth between 7% and 10%, and adjusted EPS growth between 6% and 9%.
GSK has upgraded its longer-term outlook, now expecting sales to grow more than 7% on a CAGR basis from 2021 to 2026. They also anticipate delivering over £38 billion in sales by 2031, an increase of £5 billion compared to their previous estimate.

Exclusive for Stockcircle Pro members

Sign upSign Up

Target Price by Analysts

34% upsideGSK Plc Target Price DetailsTarget Price

Current Fair Value

30.1% downside

Overvalued by 30.1% based on the discounted cash flow analysis.

Share Statistics

Market cap$93.01 Billion
Enterprise Value$109.36 Billion
Dividend Yield$1.8092 (4.03%)
Earnings per Share$3.05
Outstanding Shares2,072,462,024
Avg 30 Day Volume3,438,196


Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio14.82
Price to Sales2.51
Price to Book Ratio5.64
Enterprise Value to Revenue2.83
Enterprise Value to EBIT12.09
Enterprise Value to Net Income17
Total Debt to Enterprise0.21
Debt to Equity1.35

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Glaxosmithkline plc

CEO: Emma Walmsley